Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2023-02-27 00:00:00 ET · period of report 2023-02-23 · accession 0001209191-23-013515 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-02-27	2023-02-23	ELVN	Bauer Jake	Dir	A - Grant	—	+87.4K	87.4K	New	—
D	2023-02-27	2023-02-23	ELVN	Bauer Jake	Dir	A - Grant	$0.00	+17.7K	17.7K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-02-23	A	A	87,372	—	87,372	D	—	—	(F1) Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."
2	Derivative	Stock Option	2023-02-23	A	A	17,706	$0.00	17,706	D	$2.48 · — to 2032-08-12	17,706 Common Stock	(F2) Shares subject to the option vest in 24 equal monthly installments beginning on September 24, 2022.